FDA Okays Weekly Option in Achondroplasia - Takeaways - MDSpire

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

  • By

  • Kathryn Wighton

  • March 2, 2026

  • 2 min

Share

  • 1

    The FDA has granted accelerated approval for navepegritide (YUVIWEL) to enhance growth in pediatric patients with achondroplasia.

  • 2

    Approval was based on improvements in annualized growth velocity from three randomized clinical trials and open-label extension data.

  • 3

    Navepegritide acts as a prodrug of C-type natriuretic peptide, counteracting overactive fibroblast growth factor receptor 3 signaling.

  • 4

    Serious adverse reactions may include hypotension, with common side effects being injection site reactions.

  • 5

    Commercial availability of navepegritide in the US is expected in early Q2 2026.

Original Source(s)

FDA Okays Weekly Option in Achondroplasia

  • by Kathryn Wighton

  • March 2, 2026

Related Content

Perioperative anesthetic considerations and outcomes in Crouzon syndrome: a retrospective analysis of Le Fort III advancement surgery

Autologous pericardial vs. pulmonary artery patches for infant aortic arch reconstruction: clinical and computational morphological outcomes

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023